Halozyme Therapeutics (HALO) said late Thursday that argenx (ARGX) received the US Food and Drug Administration's approval for Vyvgart hytrulo prefilled syringe for self-injection to treat adult patients with generalized myasthenia gravis.
The company said the treatment is for anti-acetylcholine receptor antibody-positive patients and adult patients with chronic inflammatory demyelinating polyneuropathy.
The single-dose prefilled subcutaneous injection was developed in Argenx's exclusive partnership with Halozyme.
"We are delighted that Argenx continues to expand use of Halozyme's proven ENHANZE technology to support patient independence and convenience," said Helen Torley, chief executive officer of Halozyme.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。